Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
saxagliptin + oral antihyperglycemic agent
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This drug is a combination of **saxagliptin**, a dipeptidyl peptidase-4 (DPP-4) inhibitor, with another unspecified **oral antihyperglycemic agent** (typically drugs such as metformin, sulfonylurea, thiazolidinedione, etc.) for the treatment of type 2 diabetes mellitus. Saxagliptin inhibits DPP-4, an enzyme that deactivates incretin hormones, thereby increasing insulin release and decreasing glucagon levels in a glucose-dependent manner. The combination targets multiple pathophysiological mechanisms of type 2 diabetes, often aiming for improved glycemic control compared with monotherapy[4][3][1].
- Brand names
- Onglyza
- Other names
- saxagliptin + oral antihyperglycemic agentsaxagliptin plus antihyperglycemic agent
02
Targets
DPP-4 (Dipeptidyl Peptidase-IV)
Beyond the preview
Go deeper on saxagliptin + oral antihyperglycemic agent.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on saxagliptin + oral antihyperglycemic agent.